Xavier Montalban

Assessing remibrutinib in patients with relapsing MS 0:38
Assessing remibrutinib in patients with relapsing MS
Xavier Montalban • 4 Apr 2022
Addressing unanswered questions in MS at AAN 2022 0:50
Addressing unanswered questions in MS at AAN 2022
Xavier Montalban • 4 Apr 2022
Prospective cohorts on CIS and treated patients with mutiple sclerosis 1:07
Prospective cohorts on CIS and treated patients with mutiple sclerosis
Xavier Montalban • 3 Apr 2022
The safety and efficacy of evobrutinib in multiple sclerosis 1:15
The safety and efficacy of evobrutinib in multiple sclerosis
Xavier Montalban • 8 Mar 2022
Understanding the earliest stages of multiple sclerosis 1:10
Understanding the earliest stages of multiple sclerosis
Xavier Montalban • 8 Mar 2022
Using DMTs beyond patients with active MS 3:14
Using DMTs beyond patients with active MS
Xavier Montalban • 29 Mar 2022
Differential efficacy of DMTs in patients with active and inactive MS 1:30
Differential efficacy of DMTs in patients with active and inactive MS
Xavier Montalban • 29 Mar 2022
Future areas of improvement in treating MS 0:58
Future areas of improvement in treating MS
Xavier Montalban • 29 Mar 2022
Using digital technology to facilitate MS management 1:20
Using digital technology to facilitate MS management
Xavier Montalban • 29 Mar 2022
The diagnostic and therapeutic landscape of MS in 2021 2:08
The diagnostic and therapeutic landscape of MS in 2021
Xavier Montalban • 23 Sep 2021
Neuroregenerative agents in progressive multiple sclerosis 1:08
Neuroregenerative agents in progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Future directions for progressive multiple sclerosis 2:17
Future directions for progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Current treatments for primary and secondary progressive multiple sclerosis 4:46
Current treatments for primary and secondary progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
The content of VJNeurology is intended for healthcare professionals